Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.

MLA

Fionda, Laura, et al. “Eculizumab for Myasthenic Exacerbation during Treatment with Immune-Checkpoint Inhibitors.” Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 45, no. 3, Mar. 2024, pp. 1243–47. EBSCOhost, https://doi.org/10.1007/s10072-023-07190-0.

APA

Fionda, L., Rossini, E., Lauletta, A., Leonardi, L., Tufano, L., Costanzo, R., Marchetti, P., Salvetti, M., Garibaldi, M., Morino, S., & Antonini, G. (2024). Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 45(3), 1243–1247. https://doi.org/10.1007/s10072-023-07190-0

Chicago

Fionda, Laura, Elena Rossini, Antonio Lauletta, Luca Leonardi, Laura Tufano, Rocco Costanzo, Paolo Marchetti, et al. 2024. “Eculizumab for Myasthenic Exacerbation during Treatment with Immune-Checkpoint Inhibitors.” Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 45 (3): 1243–47. doi:10.1007/s10072-023-07190-0.